Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial

María Inés Figueroa, Omar Sued, Carina Cesar, Patricia Patterson, Cleyton Yamamoto, Valeria Fink, Norma Luna, Antonio Camiro-Zúñiga, Ana Gun, Pedro Cahn
doi: https://doi.org/10.1101/2022.07.08.22277426

Article usage

Article usage: July 2022 to December 2024

AbstractFullPdf
Jul 20222581041
Aug 202297436
Sep 20226413
Oct 20227706
Nov 20226703
Dec 20223103
Jan 20231314
Feb 20231616
Mar 20231913
Apr 20232031
May 20231315
Jun 2023742
Jul 2023614
Aug 202318128
Sep 20231442
Oct 20231233
Nov 20231552
Dec 20231223
Jan 2024823
Feb 2024704
Mar 2024602
Apr 2024728
May 2024502
Jun 20241337
Jul 2024607
Aug 2024927
Sep 20241603
Oct 2024953
Nov 2024405
Dec 20241002
Back to top
Posted July 09, 2022.
Download PDF
Data/Code
Email
Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial
María Inés Figueroa, Omar Sued, Carina Cesar, Patricia Patterson, Cleyton Yamamoto, Valeria Fink, Norma Luna, Antonio Camiro-Zúñiga, Ana Gun, Pedro Cahn
medRxiv 2022.07.08.22277426; doi: https://doi.org/10.1101/2022.07.08.22277426
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area